Evaxion Biotech A/S (NASDAQ:EVAX) Short Interest Down 74.2% in March

Evaxion Biotech A/S (NASDAQ:EVAX) was the recipient of a significant decline in short interest in March. As of March 15th, there was short interest totalling 22,400 shares, a decline of 74.2% from the February 28th total of 86,700 shares. Based on an average daily trading volume, of 2,260,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 2.1% of the company’s stock are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evaxion Biotech A/S stock. Catalina Capital Group LLC acquired a new stake in Evaxion Biotech A/S (NASDAQ:EVAX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned 2.98% of Evaxion Biotech A/S at the end of the most recent quarter. Hedge funds and other institutional investors own 11.04% of the company’s stock.

Analyst Ratings Changes

EVAX has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Evaxion Biotech A/S in a research report on Thursday, February 20th. Lake Street Capital dropped their target price on Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, February 4th.

Evaxion Biotech A/S Stock Performance

Shares of Evaxion Biotech A/S stock remained flat at $1.76 during mid-day trading on Friday. 39,037 shares of the company’s stock traded hands, compared to its average volume of 592,593. The stock has a market capitalization of $2.06 million, a P/E ratio of -1.21 and a beta of -0.25. The company has a quick ratio of 2.80, a current ratio of 1.00 and a debt-to-equity ratio of 7.99. The firm’s 50 day moving average is $2.51 and its 200-day moving average is $7.40. Evaxion Biotech A/S has a 1 year low of $1.67 and a 1 year high of $22.05.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.